Skip to main content

Table 1 Characteristics of studies included in the systematic review by country

From: Immunological markers of Plasmodium vivaxexposure and immunity: a systematic review and meta-analysis

Author, year [reference]

Region

Age range, years

Antibody response (type)

Study design (n)a

Plasmodium vivaxoutcomeb

Brazil

Fernandez-Becerra, 2010 [22]c

Rio Machado

DNS

PvMSP-1NT, PvMSP-119 (IgG)

CS (87)

Pv infection (LM or PCR), symptomatic Pv

Kano, 2012 [23]

Presidente Figueiredo, Amazonas

9 to 44

PvDBPII-IV, PvMSP-119 (IgG)

CS (432)

Pv infection (LM or PCR), symptomatic Pv

Lima-Junior, 2008 [24]d

Rondonia

10 to 85

PvMSP-9RIRII, PvMSP-9RII, PvMSP-9NT (IgG)

CS (282)

Pv infection

Lima-Junior, 2011 [25]

Rondonia

10 to 81

PvMSP-3αFL, PvMSP-3αNT, PvMSP-3αRI, PvMSP-3αRII, PvMSP-3αCT (IgG)

CS (282)

Pv infection

Lima-Junior, 2012 [26]

Rondonia

11 to 89

PvMSP-119 (IgG)

CS (277)

Pv infection

Nogueira, 2006 [27]

Portuchuelo, Rondonia

DNS

PvMSP-1NT, PvMSP-119 (IgG)

Cohort (173)

Pv infection

Oliveira-Ferreira, 2004 [28]

Candeias do Jamari, Rondonia

12 to 74

PvCSP (VK210, VK247, P. vivax-like) (IgG)

CS (61)

Pv infection

Souza-Silva, 2010 [29]

Acre

5 to 90

PvDBPII-IV (IgG)

Cohort (CS)e (366)

Pv infection, Pv infection (LM or PCR)

Tran, 2005 [30]f

Colina and Ribeirinha, Rondonia

11 to 75

PvRBP1 (IgG)

CS (87)

Pv infection

Versiani, 2013 [31]

Rio Pardo

DNS

PvMSP-1NT (IgG, IgG1, IgG2, IgG3, IgG4)

Cohort (CS)e (308)

Pv infection, symptomatic Pv

Indonesia

Ak, 1998 [32]

Robek

0 to 73

PvMSP-119 (IgG + IgM)

CS (169)

Pv infection

Woodberry, 2008 [33]

Timika, Papua

3 to 60

PvMSP-5 (IgG, IgM, IgG1, IgG2, IgG3, IgG4)

CC (340)

Symptomatic Pv

Papua New Guinea

Cole-Tobian, 2009 [34]

Madang

5 to 14

PvDBPII (AH, O, P, Sal 1), PvMSP-119 (IgG)

Cohortg (206)

Pv infection, Pv infection (LDR-FMA), Pv infection >150 parasites/μl

Fernandez-Becerra, 2010 [22]

Madang

0.25 to 3

PvMSP-1NT, PvMSP-119 (IgG)

CS (100)

Pv infection (LM or PCR), symptomatic Pv

King, 2008 [35]

Madang

5 to 14

PvDBPII binding inhibitory antibodies

Cohort (206)h

Pv infection

Stanisic, 2013 [36]

East Sepik

0.9 to 3.1

PvMSP-3αNT, PvMSP-3αRI, PvMSP-3αRII, PvMSP-3αCT, PvMSP-9NT, PvMSP-9RIRII (IgG)

Cohort (CS)e (183)

Pv infection (LDR-FMA), symptomatic Pv

Thailand

Fowkes, 2012 [37]

Mae Sot, Tak

15 to 42i

PvAMA1-ecto (IgG)

Nested CC (467)

Pv infection

Wongsrichanalai, 1991 [38]

Chanthaburi

DNS

PvCSP (VK210) (IgG)

CC (126)

Pv infection

Turkey

Yildiz Zeyrek, 2011 [39]

Sanliurfa

0 to 77

PvMSP-119, PvAMA1-ecto, PvSERA4, PvCSP (VK210 and VK247 chimera) (IgG, IgM, IgG1, IgG2, IgG3, IgG4)

CS (195)

Pv infection

  1. CC, case-control; CS, cross-sectional; DNS, did not state; LDR-FMA, ligase detection reaction-fluorescent microsphere assay; LM, light microscopy; PV, Plasmodium vivax.
  2. aSample size refers to number of participants for whom serology was determined.
  3. b P. vivax infection was determined by light microscopy unless otherwise stated.
  4. cFernandez-Becerra, 2010 [22] reported studies performed in two countries and features twice in Table 1.
  5. dThe studies described by Lima-Junior in 2008 and 2012 [24],[26] were conducted in the same area, but the participants were different.
  6. eCohort study with cross-sectional data also included.
  7. fTran, 2005 [30] included data from two different study sites in Brazil.
  8. gTreatment to re-infection study.
  9. hKing, 2008 [35] reported estimates from the same treatment to re-infection study as that described by Cole-Tobian, 2009 [34].
  10. iThis study comprised pregnant women.
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us